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Escherichia coli K5 heparosan was enzymatically modified by Chen and colleagues [10] to construct
a library of heparan sulfate polysaccharides for evaluation, leading to the discovery that a 2-O-sulfo-
iduronic acid residue is not essential for antithrombin-mediated anticoagulant activity in larger
oligosaccharide and polysaccharide structures.
Heparan sulfate is an anionic polysac-
charide biosynthesized in the Golgi of
eukaryotic cells through the sequen-
tial action of up to 30 biosynthetic
enzymes [1]. A specific highly sulfated
version of this glycosaminoglycan pro-
duced in mast cells, called heparin,
is commercially and therapeutically
important as a clinical anticoagulant
drug [2]. The sequence, within heparin
and heparan sulfate, primarily respon-
sible for anticoagulant activity was elu-
cidated through the elegant work of
the Lindahl and Rosenberg laborato-
ries. The structure of the antithrombin
binding site responsible for this activ-
ity is a pentasaccharide sequence of
thestructure/4)b-D-6-O-sulfoN-ace-
tyl glucosamine (1/4) b-D-glucuronic
acid (1/4) b-D-3-O-sulfo 6-O-sulfo
N-sulfo glucosamine (1/4) a-L-2-O-
sulfo iduronic acid (1/4) b-D-6-O-
sulfo N-sulfo glucosamine (1/. The
chemical synthesis of this pentasac-
charide [3] and subsequent structure-
activity relationship (SAR) studies on
this pentasaccharide demonstrated
that presence of each of the functional
groups critical for antithrombin-bind-
ing and anticoagulant activity [4].
Since the original synthesis of the
heparin pentasaccharide many ad-
vances have been made in the chemi-
cal synthesis of heparin related glycos-
aminoglycan oligosaccharides [3–5].
These improvements allow more rapid
and higher yield syntheses and have
beenapplied to thepreparationof small
libraries for oligosaccharide screening.
Unfortunately, chemical synthesis is
limited to relatively small oligosaccha-
rides (no bigger than 8–10-mer) and
requires numerous synthetic andpurifi-
cation steps. More recently, chemoen-
zymatic approaches for the synthesis
Figure 1. Chemoenzymatic Synthetic Scheme of Polysaccharide Variants of Heparan Sulfate from E. coli Heparosan
NDST is N-deacetylase N-sulfotransferase; OSTs are O-sulfotransferases; and Epi is C5 epimerase catalyzing the conversion of glucuronic acid to
iduronic acid. PAPS is required as a sulfate donor for NDST and OST enzymes.
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of heparin and related glycosamino-
glycan oligosaccharides have been
reported [6–9]. Early attempts at che-
moenzymatic synthesis relied on bio-
synthetic enzymes purified from cell
culture media and, thus, afforded very
small amounts of product [6]. Other
approaches have utilized chemical
persulfation followed by selective de-
sulfation and, while scaleable afford
unnatural structures as side-products
[7]. More recently, Liu and coworkers
chemoenzymatically synthesized hep-
aran sulfate polysaccharides with and
without anticoagulant activity using
both solution and solid phase ap-
proaches [8, 9].
In the current study by Chen, Jones,
and Liu [10], a collection of recom-
binant Escherichia coli expressed
enzymes is used to modify N-sulfo
heparosan, which had been chemoen-
zymatically prepared from E. coli K5
polysaccharides (Figure 1, adapted
from Figure 1B of [10]). Eight heparan
sulfate polysaccharides were pre-
pared by exposure of N-sulfo heparo-
san to selected biosynthetic enzymes
in the presence of the sulfo donor 30-
phosphoadenosine 50-phosphosulfate
(PAPS). The resulting polysaccharides
were characterized by disaccharide
analysis. Surprisingly, a heparan sul-
fate polysaccharide containing a re-
peating unit consisting of /4) b-D-
glucuronic acid (1/4) a-D-6-O-sulfo,
N-sulfo glucosamine (1/ called ‘‘Re-
comparin’’ showed antithrombin-me-
diated anticoagulant activity. This
activity was observed despite the ab-
sence of a 2-O-sulfo iduronic acid res-
idue found previously to be critical for
pentasaccharide binding to antithrom-
bin. Interestingly, the conformation of
the glucuronic acid residue presents
in ‘‘Recomparin’’ residue in a 4C1 con-
formation and is less flexible than the
iduronic acid residue of the pentasac-
charide, residing in an equilibrium mix-
ture of 1C4 and
2So conformers. Thus, it
appears that the flexibility presumed
to be important in pentasaccharide-
antithrombin interactions [2] is less im-
portant in polysaccharide-antithrom-
bin interactions. Finally, Liu’s group
examined the effect of chain length on
antithrombin binding (Figure 2, adap-
ted from Figure 3 of 10). These data
clearly demonstrate that for small
oligosaccharides, tetrasaccharide to
octasaccharide or decasaccharide,
the presence of 2-O-sulfo iduronic
acid residues plays a major role in
antithrombin binding but for larger
oligosaccharides, decasaccharide or
dodecasaccharide to full-length poly-
saccharide, little if any difference in
antithrombin-mediated activity can be
observed between structures with glu-
curonic acid and 2-O-sulfo iduronic
acid residues.
In conclusion, Liu and coworkers
have given the scientific community
pause when performing SAR studies
using oligosaccharides, suggesting it
might be necessary to examine both
sequence and molecular size effects
on binding and activity.
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Figure 2. Antithrombin Binding of
Oligosaccharides and Full-Length
Heparan Sulfate Polysaccharides as
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